The novel, potential antipsychotic, S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]benzopyrano [3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide), displayed ϳ25-fold higher affinity at human (h) dopamine D 3 versus hD 2L (long isoform) and hD 2S (short isoform) receptors (pK i values, 8.7, 7.1, and 7.3, respectively). Conversely, haloperidol, clozapine, olanzapine, and risperidone displayed similar affinities for hD 3 , hD 2L , and hD 2S sites. In guanosine-5Ј-O-(3-[35 S]thio)-triphosphate ([ 35 S]-GTP␥S) filtration assays, S33138 showed potent, pure, and competitive antagonist properties at hD 3 receptors, displaying pK B and pA 2 values of 8.9 and 8.7, respectively. Higher concentrations were required to block hD 2L and hD 2S receptors. Preferential antagonist properties of S33138 at hD 3 versus hD 2L receptors were underpinned in antibody capture/scintillation proximity assays (SPAs) of G␣ i3 recruitment and in measures of extracellular-regulated kinase phosphorylation. In addition, in cells cotransfected with hD 3 and hD 2L receptors that assemble into heterodimers, S33138 blocked (pK B , 8.5) the inhibitory influence of quinpirole upon forskolin-stimulated cAMP formation. S33138 had low affinity for hD 4 receptors (Ͻ5.0) but revealed weak antagonist activity at hD 1 receptors (G␣s/SPA, pK B , 6.3) and hD 5 sites (adenylyl cyclase, 6.5). Modest antagonist properties were also seen at human serotonin (5-HT) 2A receptors (G␣ q /SPA, pK B , 6.8, and inositol formation, 6.9) and at 5-HT 7 receptors (adenylyl cyclase, pK B , 7.1). In addition, S33138 antagonized h␣ 2C adrenoceptors ([ 35 S]GTP␥S, 7.2; G␣ i3 /SPA, 6.9; G␣ o /SPA, 7.3, and extracellular-regulated-kinase, 7.1) but not h␣ 2A or h␣ 2B adrenoceptors (Ͻ5.0). Finally, in contrast to haloperidol, clozapine, olanzapine, and risperidone, S33138 displayed negligible affinities for multiple subtypes of ␣ 1 -adrenoceptor, muscarinic, and histamine receptor. In conclusion, S33138 possesses a distinctive receptor-binding profile and behaves, in contrast to clinically available antipsychotics, as a preferential antagonist at hD 3 versus hD 2 receptors.Schizophrenia is a complex, progressive, and debilitating disorder of early onset that afflicts approximately 1% of the population. It is characterized by disorganized thought and a constellation of symptoms generally classified as positive (delusions and hallucinations), negative (social withdrawal, blunted affect, and mutism), and cognitive (deficits in attention, working and verbal memory, social cognition, and execArticle, publication date, and citation information can be found at http://jpet.aspetjournals.org. doi:10.1124/jpet.107.126706.ABBREVIATIONS: EPS, extrapyramidal motor symptom; AR, adrenoceptor; H 1 , histamine; DA, dopamine;3a,4, R(ϩ)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-